Cadrenal Therapeutics Inc. Common Stock
CVKD | NASDAQ
$1.09
$0 (0.00%)
Sep 22, 2026, 2:05 PM ET · Market open
Company Profile
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman & Chief Executive Officer |
| Jeffrey Cole | Chief Operating Officer |
| James J. Ferguson FACC | Chief Medical Officer |
| John Sharp | Interim CFO & Principal Accounting Officer |
| Matthew Boxer | Executive Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | S-8 | Filing |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 03, 2026 | DEFA14A | Filing |
| Aug 03, 2026 | ARS | Filing |
| Aug 03, 2026 | DEF 14A | Filing |
| Jul 23, 2026 | PRE 14A | Filing |
| Jul 21, 2026 | 8-K | Current Report |
Cadrenal Therapeutics Inc. Common Stock
| Country | United States |
| IPO Date | Jan 19, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Quang X. Pham |
Contact Details
822 A1A North Ponte Vedra,
Florida 32082 United States
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001937993 |
| CUSIP Number | 127636207 |
| ISIN Number | US1276362076 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CVKD